LinkDoc Technology Secures RMB 700 Million in Series D+ Funding to Accelerate End-to-End 'Medical Care–Pharma–Insurance' Ecosystem for Critical Illnesses

In September 2020, LinkDoc Technology, a Chinese healthcare big data unicorn, completed a RMB 700 million Series D+ financing round. New investors in this round included CICC, Youshan Capital, and the Jinnan Haihe Broadband Intelligent Industry Fund, among others. LinkDoc’s existing investors continued to participate.

Following this round of financing, LinkDoc will further focus on the core business development of its “trinity” model for novel and specialized oncology drugs. The company aims to establish a patient service system covering the entire disease treatment cycle, centered on internet hospitals, offline professional clinic pharmacies, and clinical trial recruitment for new drugs. Additionally, it will build a real-world data platform that deeply empowers the development of new oncology therapies, and create innovative insurance payment solutions oriented toward value-based healthcare and supported by medical evidence. Ultimately, LinkDoc seeks to provide end-to-end health technology solutions for major diseases within China’s healthcare industry.

LinkDoc is committed to joining hands with stakeholders across the industry to accelerate the digital transformation of China’s biopharmaceutical sector, drive the implementation of healthcare-pharmaceutical-insurance business models in the field of critical illnesses, promote the development of new infrastructure such as big data and artificial intelligence, support socio-economic development, and benefit the public.